Randomized, placebo-controlled trials have been the gold standard for evaluating the safety and efficacy of new psychotropic drugs for more than half a century. Although the US Food and Drug Administration (FDA) does not require placebo-controlled trial data to approve new drugs or marketing indications, they have become the industry standard for psychotropic drug development.
Placebos are controversial. The FDA guidelines state “when a new treatment is tested for a condition for which no effective treatment is known, there is usually no ethical problem with a study comparing the new treatment to placebo.”1 However, “in cases where an available treatment is known to prevent serious harm, such as death or irreversible morbidity, it is generally inappropriate to use a placebo control”.1(p15) When new antipsychotics are developed for schizophrenia, it can be debated which guideline applies.
Lawrence RE, Appelbaum PS, Lieberman JA. Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical? JAMA Psychiatry. Published online April 10, 2019. doi:10.1001/jamapsychiatry.2019.0275
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: